Stockscreener 앱 받기
4.28
6.20%
0.25
전일 마감가:
$4.03
열려 있는:
$4.11
하루 거래량:
385.03K
Relative Volume:
1.42
시가총액:
$89.56M
수익:
-
순이익/손실:
$-14.88M
주가수익비율:
-4.3673
EPS:
-0.98
순현금흐름:
$-10.29M
1주 성능:
-11.75%
1개월 성능:
-26.59%
6개월 성능:
-26.08%
1년 성능:
-23.57%
1일 변동 폭
$4.0612
$4.37
1주일 범위
$3.9401
$4.9491
52주 변동 폭
$3.9401
$8.29
Coya Therapeutics Inc Stock (COYA) Company Profile
명칭
Coya Therapeutics Inc
전화
650.739.3939
주소
12645 MEMORIAL DR., SUITE F1 #305, HOUSTON
COYA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
COYA
Coya Therapeutics Inc
|
4.28 | 84.33M | 0 | -14.88M | -10.29M | -0.98 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Coya Therapeutics Inc Stock (COYA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-07-09 | 개시 | Lake Street | Buy |
| 2024-12-04 | 개시 | D. Boral Capital | Buy |
Coya Therapeutics Inc 주식(COYA)의 최신 뉴스
Momentum Shift: Is PHAT currently under institutional pressureQuarterly Portfolio Review & Free Safe Entry Trade Signal Reports - baoquankhu1.vn
COYA-302: De-Risked Treg Platform With Compelling FTD Data and ALS Phase 2 Catalyst Supporting Buy Rating - TipRanks
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of “Moderate Buy” from Brokerages - Defense World
Is Coya Therapeutics Inc. stock a safe buy before earnings2025 AllTime Highs & Verified High Yield Trade Plans - Улправда
Is Coya Therapeutics Inc. stock a bargain at current levels2025 Year in Review & High Accuracy Swing Entry Alerts - Улправда
Is Coya Therapeutics Inc. stock a buy in volatile marketsJuly 2025 Trade Ideas & High Accuracy Investment Entry Signals - Улправда
Is Coya Therapeutics Inc. stock cheap compared to fundamentals2025 Key Lessons & Technical Pattern Based Buy Signals - Улправда
Support Test: How CERo Therapeutics Holdings Inc. stock benefits from global expansionTrade Analysis Report & Weekly Stock Performance Updates - ulpravda.ru
Chardan Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Aug Intraday: How Coya Therapeutics Inc. stock reacts to job market dataJuly 2025 Price Swings & Comprehensive Market Scan Reports - Улправда
Coya Therapeutics: Early COYA 302 Validation, Regulatory De-Risking, and Upcoming Catalysts Support Buy Rating - TipRanks
Coya Therapeutics, Inc. Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - marketscreener.com
How Coya Therapeutics Inc. stock reacts to job market data2025 Price Momentum & Entry and Exit Point Strategies - ulpravda.ru
COYA: Analyst Maintains Buy Rating and $15 Target Price | COYA S - GuruFocus
Coya Therapeutics Reports Positive Frontotemporal Dementia Study Data - TipRanks
Coya Therapeutics Announces Positive Study Results for FTD Treatment - TradingView — Track All Markets
Coya Therapeutics Announces Results of Investigator-Initiated Study of LD IL-2 and CTLA4-Ig Demonstrating Treg Enhancement and Cognitive Stability in Frontotemporal Dementia Patients - Business Wire
Coya Therapeutics (COYA) Analyst Rating Update: Chardan Capital - GuruFocus
Coya Therapeutics, Inc. (NASDAQ:COYA) Receives Consensus Rating of "Moderate Buy" from Brokerages - MarketBeat
Panic Selling: How Coya Therapeutics Inc stock reacts to job market dataMarket Volume Report & Technical Pattern Recognition Alerts - moha.gov.vn
Coya Therapeutics, Inc.Common Stock (NQ: COYA - FinancialContent
Coya Therapeutics: Clinical Momentum, Extended Cash Runway, and DCF-Derived Upside Support Reiterated Buy and $18 Target - TipRanks
Coya Therapeutics (NASDAQ:COYA) Given Buy Rating at D. Boral Capital - Defense World
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for CO - PharmiWeb.com
Coya Therapeutics announces FDA acceptance of COYA 302 IND application - TipRanks
US COYA 302 trial in ALS expands to Canada after regulatory nod - ALS News Today
H.C. Wainwright reiterates Buy rating on Coya Therapeutics stock at $18 - Investing.com Canada
Coya Therapeutics Announces U.S. FDA Acceptance of Investigational New Drug (IND) Application for COYA 302 for the Treatment of Frontotemporal Dementia (FTD) - BioSpace
COYA Stock Receives Consistent "Buy" Rating from D. Boral Capita - GuruFocus
Coya Therapeutics advances COYA 303 for inflammatory diseases - MSN
D. Boral Capital Reiterates "Buy" Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
(COYA) Risk Channels and Responsive Allocation - Stock Traders Daily
Coya announces Health Canada acceptance of COYA 302 clinical trial application - MSN
S P Trends: Will Coya Therapeutics Inc stock pay special dividendsJuly 2025 Price Swings & Long-Term Safe Return Strategies - Bộ Nội Vụ
Coya Therapeutics’ (COYA) Buy Rating Reaffirmed at D. Boral Capital - Defense World
Is Coya Therapeutics Stock Built to Withstand More Downside? - Trefis
Coya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - BioSpace
Trading the Move, Not the Narrative: (COYA) Edition - Stock Traders Daily
D. Boral Capital Maintains Coya Therapeutics (COYA) Buy Recommendation - Nasdaq
D. Boral Capital Reaffirms Buy Rating for Coya Therapeutics (NASDAQ:COYA) - MarketBeat
Coya Therapeutics receives clinical trial application acceptance from Health Canada - marketscreener.com
Coya Therapeutics, Inc. Receives Clinical Trial Application Acceptance from Health Canada to Proceed with the COYA302 Alstars Trial for the Treatment of Amyotrophic Lateral Sclerosis - marketscreener.com
Workboat Indexes | WorkBoatCoya Therapeutics Receives Clinical Trial Application (CTA) Acceptance from Health Canada to Proceed with the COYA 302 ALSTARS Trial for the Treatment of Amyotrophic Lateral Sclerosis (ALS) - FinancialContent
Coya Therapeutics receives $4.2M milestone payment - MSN
Moving Averages: Why retail investors pile into Coya Therapeutics Inc. stockEarnings Recap Report & Reliable Entry Point Alerts - Улправда
Why retail investors pile into Coya Therapeutics Inc. stock2025 Trading Volume Trends & Low Volatility Stock Recommendations - Улправда
Analyst Upgrade: Is Coya Therapeutics Inc. stock a bargain at current levels2025 Volatility Report & Capital Protection Trading Alerts - DonanımHaber
Can Coya Therapeutics Inc. stock maintain operating marginsJuly 2025 Big Picture & Safe Capital Investment Plans - Улправда
Coya Therapeutics Receives $4.2M Milestone Payment - TipRanks
Coya Therapeutics Receives Milestone Payment for ALS Trial - TradingView — Track All Markets
Coya Therapeutics (NASDAQ: COYA) reports $4.2 million ALS trial payment - Stock Titan
Coya Therapeutics Inc (COYA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
4.73%
0.92%
자본화:
|
볼륨(24시간):